Med Lett Drugs Ther. 2011 Sep 5;53(1372):69-70.
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. Clopidogrel is expected to become available generically in the US within the next few months.
美国食品药品监督管理局（FDA）已批准口服抗血小板药物替格瑞洛（商品名：倍林达，阿斯利康公司生产）与低剂量阿司匹林联合使用，以降低急性冠脉综合征（ACS）患者的血栓性心血管事件发生率。在这一用途上，它将与氯吡格雷（商品名：波立维）和普拉格雷（商品名：Effient）展开竞争。预计氯吡格雷在未来几个月内将在美国以非专利药形式上市。
